VIDEO: CSO Marilyn Anderson interviewed by the Australian Academy of Science.

Nov 29, 2017 | News, Presentations

See Hexima’s Chief Science Officer, Prof Marilyn Anderson, talking about our new treatment for toenail fungus in this new video by the Australian Academy of Science. View video here

Hexima receives approval to conduct a phase 1/2a study for fungal nail infections

Nov 21, 2017 | News

Hexima Limited is pleased to announce today that it has received Human Research Ethics Committee approval to conduct a phase 1/2a clinical trial of HXP124 in patients with fungal nail infections. Hexima’s CEO Dr Nicole van der Weerden said “Obtaining ethics approval...

Hexima Shareholder Update and Share Trading

Jun 16, 2017 | Investor updates, News

Dear Shareholder View the latest shareholder update from Hexima Limited Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to...

Hexima commences research into application of plant defensin technology in Candidaemias and Candida-based biofilms

Jun 9, 2017 | News

Hexima is pleased to announce the commencement of a project to assess the application of Hexima’s antifungal technology in control of medically important Candidaemias and Candida-based biofilms. Systemic Candida infections are a major problem in immunocompromised...

Hexima presents Human Antifungal Technology at ASM Microbe 2016

Jun 20, 2016 | News, Presentations

Hexima’s Chief Science Officer, Professor Marilyn Anderson, Onychomycosis Project Leader, Dr Michael Baker and Researcher, Dr Brigitte Hayes, have presented Hexima’s human antifungal technology at ASM Microbe 2016. The conference is an opportunity to showcase the...

Hexima announces commercial licence for Multi-Gene Expression Vehicle Technology

Jun 8, 2016 | News

Hexima has executed its first commercial licence for the Multi-Gene Expression Vehicle (MGEV) technology. This is an exciting milestone for the company. Long term collaborator DuPont Pioneer has exercised its commercial option under an existing research licence to...